Genetics and epigenetics of glioblastoma: Applications and Overall Incidence of IDH1 Mutation

Frontiers in Oncology

Volumn 6, Issue JAN, 2016, Pages

  Liu, Aizhen ^a   Hou, Chunfeng ^a   Chen, Hongfang ^a   Zong, Xuan ^b   Zong, Peijun ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Epigenetics; Genetics; Glioblastoma; IDH1 mutation

Indexed keywords

HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 9; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYL CPG BINDING PROTEIN 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLATELET DERIVED GROWTH FACTOR B; PROTEIN MLH1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GLIOBLASTOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

EID: 84958181186     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00016     Document Type: Article

References (60)

1. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 170:1445-53. doi:10.2353/ajpath.2007.070011
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459-66. doi:10.1016/S1470-2045(09)70025-7
4. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 462:739-44. doi:10.1038/nature08617
5. Cancer Genome Atlas Research. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061-8. doi:10.1038/nature07385
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321:1807-12. doi:10.1126/science.1164382
7. Geisbrecht BV, Liang X, Morrell JC, Schulz H, Gould SJ. The mouse gene PDCR encodes a peroxisomal delta(2), delta(4)-dienoyl-CoA reductase. J Biol Chem (1999) 274:25814-20. doi:10.1074/jbc.274.36.25814
8. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alphaHG. Biochemistry (2011) 50:4804-12. doi:10.1021/bi200499m
9. Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathol Commun (2014) 2:19. doi:10.1186/2051-5960-2-19
10. Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus (2013) 34:E2. doi:10.3171/2012.12.FOCUS12355
11. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 116:597-602. doi:10.1007/s00401-008-0455-2
12. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 361:1058-66. doi:10.1056/NEJMoa0903840
13. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 116:2122-6. doi:10.1182/blood-2009-11-250878
14. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 24:1094-6. doi:10.1038/leu.2010.52
15. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2013) 32:3091-100. doi:10.1038/onc.2012.315
16. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 224:334-43. doi:10.1002/path.2913
17. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet (2011) 43:1262-5. doi:10.1038/ng.994
18. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol (2011) 21:74-87. doi:10.1111/j.1750-3639.2010.00454.x
19. Setty P, Hammes J, Rothamel T, Vladimirova V, Kramm CM, Pietsch T, et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn (2010) 12:750-6. doi:10.2353/jmoldx.2010.090237
20. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, et al. PCR-and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol (2010) 20:298-300. doi:10.1111/j.1750-3639.2009.00327.x
21. Boisselier B, Marie Y, Labussiere M, Ciccarino P, Desestret V, Wang X, et al. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat (2010) 31:1360-5. doi:10.1002/humu.21365
22. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 2:146-58. doi:10.1002/emmm.201000070
23. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 4:e7887. doi:10.1371/journal.pone.0007887
24. Boisselier B, Gallego Perez-Larraya J, Rossetto M, Labussiere M, Ciccarino P, Marie Y, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology (2012) 79:1693-8. doi:10.1212/WNL.0b013e31826e9b0a
25. Berenstein R, Blau IW, Kar A, Cay R, Sindram A, Seide C, et al. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia. J Exp Clin Cancer Res (2014) 33:44. doi:10.1186/1756-9966-33-44
26. Catteau A, Girardi H, Monville F, Poggionovo C, Carpentier S, Frayssinet V, et al. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun (2014) 2:58. doi:10.1186/2051-5960-2-58
27. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol (2011) 121:241-52. doi:10.1007/s00401-010-0770-2
28. Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol (2011) 28:115-23. doi:10.1007/s10014-011-0023-7
29. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol (2011) 70:110-5. doi:10.1097/NEN.0b013e31820565f9
30. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 17:225-34. doi:10.1016/j.ccr.2010.01.020
31. Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, Weller M, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer (2012) 131:766-8. doi:10.1002/ijc.26425
32. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol (2012) 33:1349-55. doi:10.3174/ajnr. A2950
33. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2012) 107:197-205. doi:10.1007/s11060-011-0737-8
34. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med (2012) 18:624-9. doi:10.1038/nm.2682
35. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med (2012) 4:116ra114. doi:10.1126/scitranslmed.3002693
36. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 11:341-7. doi:10.1215/15228517-2009-025
37. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 27:4150-4. doi:10.1200/JCO.2009.21.9832
38. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 360:765-73. doi:10.1056/NEJMoa0808710
39. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, et al. Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat (2010) 31:E1186-99. doi:10.1002/humu.21201
40. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 74:1886-90. doi:10.1212/WNL.0b013e3181e1cf3a
41. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res (2010) 16:1597-604. doi:10.1158/1078-0432.CCR-09-2902
42. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 27:5874-80. doi:10.1200/JCO.2009.23.6497
43. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology (2009) 73:1792-5. doi:10.1212/WNL.0b013e3181c34ace
44. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol (2010) 120:719-29. doi:10.1007/s00401-010-0777-8
45. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 177:2708-14. doi:10.2353/ajpath.2010.100680
46. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology (2010) 75:1560-6. doi:10.1212/WNL.0b013e3181f96282
47. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res (2011) 17:4588-99. doi:10.1158/1078-0432.CCR-10-3194
48. Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget (2012) 3:774-82. doi:10.18632/oncotarget.577
49. Jones PA, Baylin SB. The epigenomics of cancer. Cell (2007) 128:683-92. doi:10.1016/j.cell.2007.01.029
50. Kloosterhof NK, de Rooi JJ, Kros M, Eilers PH, Sillevis Smitt PA, van den Bent MJ, et al. Molecular subtypes of glioma identified by genome-wide methylation profiling. Genes Chromosomes Cancer (2013) 52:665-74. doi:10.1002/gcc.22062
51. Cadieux B, Ching TT, VandenBerg SR, Costello JF. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res (2006) 66:8469-76. doi:10.1158/0008-5472.CAN-06-1547
52. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet (2007) 39:457-66. doi:10.1038/ng1990
53. Caren H, Pollard SM, Beck S. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. Mol Aspects Med (2013) 34:849-62. doi:10.1016/j.mam.2012.06.007
54. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics (2009) 4:255-64. doi:10.4161/epi.9130
55. Gotze S, Wolter M, Reifenberger G, Muller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer (2010) 126:2584-93. doi:10.1002/ijc.24981
56. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 11:147-60. doi:10.1016/j.ccr.2006.11.023
57. Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T, et al. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia (2005) 7:193-9. doi:10.1593/neo.04490
58. Zhou H, Miki R, Eeva M, Fike FM, Seligson D, Yang L, et al. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res (2007) 13:2344-53. doi:10.1158/1078-0432.CCR-06-2303
59. Hayry V, Tanner M, Blom T, Tynninen O, Roselli A, Ollikainen M, et al. Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol (2008) 116:97-102. doi:10.1007/s00401-008-0376-0
60. Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer (2008) 8:243. doi:10.1186/1471-2407-8-243